What does ONFH stand for?

Osteonecrosis of the Femoral Head

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Ontario North Fishing Adventures (Ontario, Canada) Ontario Nuclear Funds Agreement Opera Nazionale Figli Aviatori Orkney Norway Friendship Association (Orkney Islands, Scotland) Other Net Foreign Assets Overall New Funds Account Oman National Fisheries Company (est. 1980) Ontario Natural Food Co-op (Canada) Office of the Non-Formal Education Commission (Thailand) Ontario Native Fire Fighters Society		Old Northside Foundation, Inc. (Indianapolis, Indiana) Open NAND Flash Interface (working group) Optical Network Focused Interest Group Open Nederlandse Fanfare Kampioenschappen (Dutch band competition; Netherlands) National Office for the Family and Population (Tunisia) Oparta Na Faktach Rymonacja (Polish: Based on the Facts Rymonacja; band) Ohio National Financial Services Inc. (Cincinnati, OH) Operating Nuclear Facility Safety (American Nuclear Society) Observable Non-Deterministic Finite State Machine Mornington, Queensland, Australia - Mornington Is (Airport Code)

Samples in periodicals archive:

Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents.

Bisphosphonate use and osteonecrosis of the jaw: association or risk ...

Etiology of Pain in Early Osteonecrosis of the Femoral Head Abstract & Commentary Synopsis: Serial MR images were used to correlate the course of marrow edema in the femoral head with hip pain prior to collapse.

Etiology of Pain in Early Osteonecrosis of the Femoral Head

Currently, the Company has a vascular regeneration product in clinical development for the treatment of critical limb ischemia (called the RESTORE-CLI trial), a bone regeneration product in Phase III development for the treatment of osteonecrosis of the femoral head (called the ON-CORE trial), a cardiac regeneration product in clinical development for dilated cardiomyopathy and a preclinical research program targeting unmet needs in neural health.

Webcast Alert: Aastrom Announces Third Quarter Investor Conference ...

Currently, the Company has a bone regeneration product in Phase III development for the treatment of osteonecrosis of the femoral head (called the ON-CORE trial), a vascular regeneration product in Phase IIb development for the treatment of critical limb ischemia (called the RESTORE-CLI trial), and preclinical research programs targeting unmet needs in cardiac and neural health.

Webcast Alert: Aastrom Announces Conference Call to Discuss the ...

TRC-based products have been used in over 250 patients to date and are being clinically evaluated for bone regeneration as a result of osteonecrosis of the femoral head (U.

Webcast Alert: Aastrom Announces Fourth Quarter Investor Conference ...

TRCs have received Orphan Drug Designation from the FDA for use in the treatment of osteonecrosis of the femoral head and the treatment of dilated cardiomyopathy, a severe chronic disease of the heart.

Webcast Alert: Aastrom Announces Its Third Quarter Investor ...

TRCs have received Orphan Drug Designation from the FDA for use in the treatment of osteonecrosis of the femoral head and dilated cardiomyopathy.

Webcast Alert: Aastrom Biosciences Announces Its Second Quarter ...

Food and Drug Administration for use in the treatment of osteonecrosis of the femoral head.

Webcast Alert: Aastrom Biosciences Announces Its First Quarter ...